CAPTIVATE study shows an Imbruvica + Venclexta combination has potential for remission in CLL/SLL patients.- AbbVie

The ibrutinib and venetoclax cohort met its primary endpoint of complete response (CR) rate of 56% (95% CI 48-64) among patients without del(17p), 70 years old or younger and with 27.9 months of follow up. This rate was higher than the 37% minimum meaningful rate study assumption (P<0.0001). the cr rate was consistent across all patients in the study including high-risk cll patient groups. furthermore, 24-month progression free survival (pfs) and overall survival (os) were 95% and 98%, respectively. while the interim data reported for the phase ii captivate study are promising, a larger-scale phase iii study is also essential, which commenced in april 2018 in the treatment-naïve patient population, but excludes those with high-risk 17p deletion and or p53 mutation. the superior efficacy that has so far been reported for imbruvica + venclexta, which may ultimately suggest a curative capacity for the regimen, as well as its potential as a time-limited therapy that would reduce treatment-related toxicities in patients, all contribute to the optimistic outlook for the combination therapy in cll.></0.0001).>